{
  "name" : "dacemirror.sci-hub.se_journal-article_62ad9b94741868953797641ba171d9fd_xuan2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "High-Security Multifunctional Nano-Bismuth-Sphere-Cluster Prepared from Oral Gastric Drug for CT/PA Dual-Mode Imaging and Chemo-Photothermal Combined Therapy In Vivo",
    "authors" : [ "Yang Xuan", "Xiao-Quan Yang", "Zi-Yu Song", "Ruo-Yun Zhang", "Dong-Hui Zhao", "Xiao-Lin Hou", "Xian-Lin Song", "Bo Liu", "Yuan-Di Zhao", "Wei Chen" ],
    "emails" : [ "zydi@mail.hust.edu.cn;", "chen1980wei@mail.hust.edu.cn" ],
    "sections" : [ {
      "heading" : null,
      "text" : "FULL PAPER www.afm-journal.de\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1900017 (1 of 12)"
    }, {
      "heading" : "High-Security Multifunctional Nano-Bismuth-Sphere-Cluster",
      "text" : ""
    }, {
      "heading" : "Prepared from Oral Gastric Drug for CT/PA Dual-Mode",
      "text" : ""
    }, {
      "heading" : "Imaging and Chemo-Photothermal Combined Therapy",
      "text" : "In Vivo\nYang Xuan, Xiao-Quan Yang, Zi-Yu Song, Ruo-Yun Zhang, Dong-Hui Zhao, Xiao-Lin Hou,"
    }, {
      "heading" : "Xian-Lin Song, Bo Liu, Yuan-Di Zhao,* and Wei Chen*",
      "text" : "Multifunctional nanoprobes that can be applied for real-time monitoring or precision treatment of tumors have received wide interest among researchers. However, most of these nanoprobes are obtained through chemical synthesis, and thereby may contain toxic residues or harmful reagents. In this article, a nano-bismuth-sphere-cluster (Bi) is synthesized via a one-step method (after an irradiation with ultra-violet) and is then applied in dual-mode computed tomography/photoacoustic imaging. Bismuth potassium citrate granules, which is a common gastric drug that is highly safe and has a low price (<1 China Yuan/g), is used as the only raw material. The results show that the Bi cluster has good stability with sizes of about 25–55 nm, and a photothermal conversion efficiency as high as 39.67%. After being adsorbed onto doxorubicin, the Bi cluster can be used directly in animal experiments. Due to the effect of enhanced permeability and retention, the probe can easily enter tumor cells. Drug release can be controlled by a near-infrared laser and the acidic environment of tumor cells, which indicates that the combined chemo-photothermal therapy is achieved. This work presents a new dual-mode bio-imaging and combined chemo-photothermal therapeutic nanoprobe that can be applied in theragnostics for tumors.\nDOI: 10.1002/adfm.201900017\nY. Xuan, R.-Y. Zhang, D.-H. Zhao, X.-L. Hou, X.-L. Song, B. Liu, Prof. Y.-D. Zhao, Dr. W. Chen Britton Chance Center for Biomedical Photonics at Wuhan National Laboratory for Optoelectronics – Hubei Bioinformatics & Molecular Imaging Key Laboratory Department of Biomedical Engineering College of Life Science and Technology Huazhong University of Science and Technology Wuhan, 430074 Hubei, P. R. China E-mail: zydi@mail.hust.edu.cn; chen1980wei@mail.hust.edu.cn Prof. X.-Q. Yang, Prof. Y.-D. Zhao Key Laboratory of Biomedical Photonics (HUST) Ministry of Education Huazhong University of Science and Technology Wuhan, 430074 Hubei, P. R. China Z.-Y. Song Faculty of Management and Economics Dalian University of Technology Dalian, 116024 Liaoning, P. R. China\nThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adfm.201900017.\n1. Introduction\nCancer is a serious threat to human health and life, especially for those in developing countries, in which cancer screening and early diagnosis technology is less effective; as a result, cancer is generally found at later stage. Additionally, due to low efficacy of cancer treatment, as well as side effect, and high rates of cancer recurrence and metastasis, complete cure of cancer can be difficult. Therefore, it is of great significance to explore safe and simple technique for diagnosis and treatment of cancer patients to improve their survival rate.\nVarious imaging techniques including computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography, fluorescence imaging (FI), photoacoustic imaging (PAI), and ultrasound imaging play an important role in the diagnosis of tumor. These techniques have different principles, thus have their\nown unique advantage and limitation.[1] Single mode imaging cannot meet all the requirements of tumor diagnosis. Currently, there are different emerging dual-mode imaging or multi-mode imaging methods,[2] such as MRI/FI,[3] MRI/CT,[4] CT/FI,[5] PAI/ FI,[6] and CT/MRI/FI.[7] In these modes, researchers generally applied multifunctional probe to obtain different imaging information from a single contrast agent. More disease information can be obtained from multi-mode imaging. Early diagnosis of tumor can significantly increase the curing rate of cancer patient,[8] and multi-mode imaging can greatly help improve the accuracy of early diagnosis and reduce the risk of misdiagnosis. Multi-mode imaging not only can reduce the number of examination and the dose of contrast agent, but also can be used to obtain multi-dimensional information. Therefore, the use of multi-mode imaging in early diagnosis and efficient monitoring of tumor is inevitable. In efforts to develop multifunctional probe, numerous nanomaterials with good imaging capability have been achieved, such as nano gold star[9] (used in CT and PAI), superparamagnetic iron oxide nanoparticle (used in MRI),[10] and quantum dot (used in FI).[6] Therefore,\nDual-Mode Imaging\nAdv. Funct. Mater. 2019, 1900017\n1900017 (2 of 12) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nresearchers often use this type of nanomaterial for the purpose of achieving multi-mode imaging. The use of combined CT and PAI is ideal for dual-mode imaging: CT provides spatial information of deep tissue, while PAI gives information on the location and distribution of trace amount of tumor-related molecules in the tissue. With such combination, highly sensitive molecular information of the disease and high-resolution pathological image can be obtained simultaneously. This can provide imaging data for early diagnosis and/or treatment of tumor.[9]\nIn recent years, photothermal therapy (PTT), an efficacious tumor therapy, has attracted considerable attention from researchers. In this therapy, near-infrared (NIR) light is used to increase the temperature of tumor site to the efficacious therapy value (>41 °C). When high temperature is maintained for a certain period of time, cancer cells are killed, while normal cells remain safe because they can tolerate high temperature. PTT damages neither normal tissues nor immune system; thus it is often used in cancer treatment along with other traditional methods, such as surgery, radiotherapy, and chemotherapy. Because NIR light has good tissue penetration ability, the photothermal agent localized at the tumor site absorbs NIR light to generate heat that causes irreversible harm to tumor cells. Therefore, photothermal agent plays an important role in PTT.[11,12] However, some studies have shown that inefficient deep tissue penetration of NIR light, due to absorption and scattering, can lead to insufficient accumulation of heat in tumor cells, in turn can usually result in tumor recurrence.[13] Thus, to more effectively kill tumor cell, PTT is used in combination with chemotherapy.[14] Recent clinical researches have shown that, besides its direct lethal effect on cancer, PTT could enhance the therapeutic effect of chemotherapy, and inhibit cancer recurrence and metastasis. Heat generated by PTT is believed to help chemotherapy drug to enter into tumor tissue and increase its cytotoxic effect.[8] This dual-mode combined therapy has attracted much attention from researchers in recent years. Some nanomaterials for imaging, such as gold nanorod/ shell/star[9,15,16] and Ag2S quantum dot,[6] have also been found to possess photothermal property. Integrated probes for diagnosis and treatment of tumor can be developed based on these materials.\nTo meet the requirements of PTT (deep tumor penetration and low dose of probe), the screening of photothermal agent with high photothermal conversion efficiency has increasingly become one of the research focuses. However, regardless of the type of contrast agent or photothermal agent used, price and safety are important problems that cannot be ignored. The nanomaterials are usually synthesized from expensive chemical reagents, and toxic reagents are often needed during the synthesis or purification, thereby it may pose hidden health risks. It is therefore important to synthesize multi-functional probes from safe, inexpensive, and simple raw materials for diagnosis and treatment of cancer.\nElemental bismuth has unique application in medicine; for example, it can be used as stomach drug. Owing to its high X-ray absorption coefficient (5.739 cm2 g−1 at 100 keV), bismuth is a theoretically excellent CT contrast agent. Additionally, researchers have found that bismuth is a rare multi-functional nanomaterial that has both photoacoustic and photothermal\nproperties. In this work, bismuth potassium citrate (BPC) granule, a low-price stomach medicine (<1 China Yuan/g), was used as the only raw material to synthesize nano-bismuthsphere-cluster(Bi) with dual-mode imaging function in CT/PA by one-step method, after being irradiated with ultra-violet (UV) for 3 min. Bi was found to not only be safe for use in vivo, but also have high conversion efficiency, uniform size, excellent stability, and low toxicity. After being adsorbed on doxorubicin, it could be used directly in animal experiment. This study demonstrates that the established Bi cluster could be used in dualmode imaging and in combined chemo-photothermal therapy of tumor in vivo."
    }, {
      "heading" : "2. Results and Discussion",
      "text" : "In this article, a low-price stomach medicine BPC (<1 China Yuan/g) was used as the only raw material in the synthesis of Bi using a one-step method and UV irradiation (Figure 1). It was deduced Bi cluster was wrapped by sodium carboxymethyl cellulose (CMC) in the oral gastric drug as auxiliary material, and CMC has been proved to have good abilities of loading drug and controlled release, it also presented guaranteeing safety in injecting. It was inferred that citrate and UV light played important roles. Bismuth ion was reduced by citrate in bismuth potassium citrate, and its electron transfer could be promoted by UV light, then after that, nano-bismuth-spherecluster was obtained.[17] The results from dynamic light scattering and transmission electron microscopy (TEM) showed that Bi had uniform sizes with average particle size of about 25–55 nm (Figure 2A,B). High-resolution TEM further showed that Bi had a typical lattice structure with a lattice spacing of about 0.336 nm, which corresponds to the crystal plane spacing of bismuth of (012) (Figure 2B, inset). The peaks at 4f7 and 4f5 in X-ray photoelectron spectroscopy (XPS) are the characteristic peaks of bismuth element (Figure 2C), and the X-ray powder diffraction (XRD) pattern showed the standard spectrum of the elemental bismuth (Figure 2D). These data confirm that bismuth nanoparticle was successfully synthesized. The absorption spectra showed that Bi can absorb NIR light (Figure 2E), indicating that it may have photothermal effect after being irradiated by NIR laser. The synthesis method of Bi is simple, and the raw material is easy to obtain. A quantity of 1 g of stomach medicine could prepare about 250 mg nano-bismuth-spherecluster after UV irradiation. (Figure 2E, inset). The results from thermogravimetric analysis (TGA) showed that the weights of Bi and DOX@Bi decreased sharply at about 200 °C because the decomposition temperature of citric acid is around 200 °C. The weight decreased slowly when the temperature reached 275 °C, which is the fusion point of sodium carboxymethyl cellulose. Citric acid and sodium carboxymethyl cellulose are the main ingredients of the stomach medicine. When the temperature reached its boiling point at 527 °C, the quality was sharply declined. The difference between the two species appeared at about 762 °C, which approached the boiling point of DOX.[18] While there was no change in Bi, a decline in weight was observed in DOX@Bi; this indicated that DOX successfully adsorbed onto the surface of DOX@Bi (Figure 2F). This experiment also proved that citric acid and sodium carboxymethyl\nAdv. Funct. Mater. 2019, 1900017\n1900017 (3 of 12) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\ncellulose were mixed with Bi. These two molecules could provide stability to Bi. After being stored at 37 °C for 27 d, changes of size, zeta potential, PDI, and visual sense of Bi were not obvious (Figure 2G–I), thus suggesting that the probe has excellent stability under the protection of stabilizer.\nThe results showed that Bi is excellent PA and CT imaging agents. The PAI results showed that intensity of PA signal linearly increased with increasing Bi concentration (Figure 3A). The CT imaging results showed there was a good linear relationship between probe concentration and HU value, and the image quality was twice higher than that obtained with iodine under the same condition (Figure 3B). Additionally, the data showed that Bi was able to adsorb DOX. At a constant Bi mass, the loading efficiency increased with increasing DOX mass, while the encapsulation efficiency decreased (Figure 3C). By contrast, at a constant DOX mass, the loading efficiency decreased with increasing Bi mass, while the encapsulation efficiency increased (Figure 3D). Considering the therapeutic effect and overall cost, Bi:DOX at a mass ratio of 25:1 was selected as the optimal ratio. Drug release behavior was subsequently investigated, and the results showed that acidic environment could accelerate DOX release (Figure 3E). For the pH-sensitive DOX release from the probe, it was known that it was related to the increased hydrophilicity and solubility of DOX at acidic pH; besides, the intermolecular force between carrier and DOX was also decreased in acidic environment,[19] these both caused DOX faster release in acidic environment.\nDOX could be released a little when DOX@Bi is circulated in blood, which presents neutral pH. However, it released large\nnumber of drug only when DOX@Bi entered into tumor cells, which had an acidic environment. This targeted release of drug could not only improve the utilization rate of the drug, but also reduce the toxicity to normal cells, as well as other side effects. Further studies showed that the drug release could be controlled by NIR laser. When the suspension was irradiated with NIR laser, the amount of released DOX rapidly increased. The release of DOX was 54 ± 2.5% after 10 min irradiation, which is significantly different from the release without laser irradiation (12.16 ± 4.9%; Figure 3F). For the controlled release by NIR laser, it was considered as the probe presented good photothermal performance, high temperature could weaken the hydrogen-bonding between DOX and CMC, thus leading to the release of drug. After laser off, the DOX release became very slow in a short time; during this “off” period, it was thought DOX was still released from probe; however, the rate was far less than laser “on” period.\nDrug-controlled release caused by laser irradiation was because of the photothermal properties of the probe. When the laser power was kept constant, the temperature increased with the increase of Bi concentration, and reached its maximum value at Bi concentration of 1 mg mL−1. In contrast, there was no obvious photothermal effect by 4 mg mL−1 BPC in control group (Figure 4A,B), which confirms that the photothermal effect is not the result of the stomach drug alone. With a constant BPC concentration, the temperature of Bi increased with the increase of laser power density (Figure 4A,C). The temperature change of probe after several cycles of laser irradiation showed that Bi has good photothermal stability\nAdv. Funct. Mater. 2019, 1900017\nFigure 1. Synthesis process of DOX@Bi. PA/CT dual-mode imaging and combined chemo-photothermal tumor therapy in vitro and in vivo.\n1900017 (4 of 12) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Funct. Mater. 2019, 1900017\nFigure 3. PA response to different concentrations of Bi (0.3, 0.6, 0.9, 1.2, and 1.5 mg mL−1) (A, inset: PAI of Bi). CT response to different concentrations of Bi (0.3, 0.6, 0.9, 1.2, and 1.5 mg mL−1) and iohexol (B, inset: CT imaging of Bi). Changes in encapsulation efficiency and loading efficiency with respect to a constant DOX mass (40 µg) and different Bi masses (C). Changes in encapsulation efficiency and loading efficiency with respect to a constant Bi mass (500 µg) and different DOX masses (D). DOX-release efficiency of DOX@Bi under different pH (E) and different laser conditions (pH = 7.4, F). **p < 0.01, n = 3.\nFigure 2. A) Dynamic light scattering (n = 5), B) TEM (inset: high-resolution TEM), C) XPS result, and D) XRD diffraction spectrum of Bi. E) Absorption spectra of BPC and Bi (inset: the digital photograph of large-scale product by once synthesis from 1 g gastric drug). F) TGA curves of Bi and DOX@Bi. G) Changes in size, H) zeta potential, and I) PDI of Bi at 37 °C (n = 5; inset: digital photographs of Bi at 37 °C).\n1900017 (5 of 12) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\n(Figure 4E). According to the equation: = ( ) (1 10 ) max surr Dis 808 hs T T Q I A η − − − − [20]; where hs = mc/τ, QDis = hs × (Tmax of water − Tsurr), m is the mass of solution (g), c is the specific heat capacity of water (J/g·°C), I is the laser power (W), A808 is the absorption at 808 nm, and τ equaled to 378.43 s. Finally, the calculated photothermal conversion efficiency (η) was 39.67% (Figure 4D), which is much higher than that of most other existing nanomaterials, such as gold nanorod (21%),[21] copper sulfide (25.7%),[22] and bismuth nanodot (30%).[23] These results show that Bi has excellent photothermal conversion, which was highly useful characteristic for PTT of tumor.\nThe toxicity of the probe is a key factor influencing its application; thus, its influence on hemolysis of red blood cell was investigated. The results showed that red blood cell has a hemolysis ratio of less than 0.74% after being incubated with Bi at a maximum concentration (400 µg mL−1) for 8 h. This indicates that the Bi has excellent blood compatibility (Figure 5A). The MTT results also confirmed that the probe has no significant toxicity to both 3T3 and 4T1 cells. After being treated with Bi at a concentration of as high as 1000 µg mL−1, the two types of cells still had high survival rate (81 ± 1.1 and 80 ± 4.0% for 3T3 and 4T1 cells, respectively; Figure 5B). Low toxicity and\ngood biocompatibility are foundations for successful in vitro and in vivo experiments. With increasing incubation time, higher amount of probe could enter into cell, as indicated by the increased signal intensity of CT and PA (Figure 5C,D). TEM of ultrathin section showed black spots of the probe distributing throughout the cell (Figure 5H), whereas these spots were not found in blank control cells (Figure 5G).\n4T1 cells that were incubated with Bi for different time, followed by irradiation with a laser for 5 min had increased dead cell with increasing incubation time, as indicated by PI staining (red; Figure 5E). It appears that prolonged incubation time allows higher amount of probe to enter into the cells, thereby the photothermal treatment effect became more obvious. The therapeutic effect of DOX@Bi on 4T1 cells was determined using MTT assay (Figure 5F). Since the probe contained a constant drug concentration, DOX concentration was used in subsequent experiment to calibrate the amount of probe added in different treatments, unless otherwise noted. The results indicated that laser irradiation hardly had effect on cell viability. While low concentration of single DOX could kill nearly half of the tumor cells, single Bi with laser irradiation could barely kill them. Photothermal effect was significantly\nAdv. Funct. Mater. 2019, 1900017\nFigure 4. Changes of temperature of BPC and different concentrations of Bi after irradiation by 1.0 W cm−2 laser over time (A, B). Changes of temperature of 0.25 mg mL−1 Bi after irradiation by laser with different power densities over time (A, C). Photothermal conversion efficiency (D) and thermal stability of probe (E).\n1900017 (6 of 12) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nbetter than chemotherapy when the concentration of DOX was over 8 µg mL−1 (*p < 0.05). The effect of combined chemophotothermal therapy was significantly different from that of single drug or single photothermal therapy (*p < 0.05); however, the difference was significant when the probe concentration was higher than 6 µg mL−1 (**p < 0.01).\nThe CLSM of free DOX and DOX@Bi have been completed (Figure 5I). It was seen that when the DOX@Bi was incubated with cell for 8 h, there was weak fluorescence of DOX in the cell due to its fluorescence quenching by Bi. Free DOX can be taken into nucleus easily. When DOX@Bi was incubated with cell for 8 h and irradiated by laser, there was obvious DOX fluorescence in the cytoplasm, indicating the release of DOX from probe, and it was also found DOX still has not been taken into\nnucleus. After 2 h culture, it showed DOX began to enter the nucleus clearly, demonstrating the ability of Bi cluster for delivering DOX in vitro.\nThe probe was applied in in vivo studies. After the tumor of mice grew to a certain volume, it was injected through caudal vein with the probe, and PA and CT imaging were carried out in vivo using PA and CT imaging systems, respectively. The results showed that with increasing time, the probe became more apparent at the tumor site. While its intensity reached a maximum value at 12 h, the probe could be hardly observed after 24 h (Figure 6A,B). The results indicate the effectiveness of the probe in in vitro PTT, in vivo PA and CT imaging; thus, PTT was further carried out in vivo. Six groups of tumor-bearing mice were injected through caudal vein with different probes (PBS, DOX,\nAdv. Funct. Mater. 2019, 1900017\nFigure 5. A) Percent of hemolytic red blood cell after being incubated with Bi at various concentrations for different times (inset: a digital photograph of hemolytic result). B) Cytotoxicity of Bi determined by MTT assay (n = 5). C) PAI and D) CT of 4T1 cells treated with probe for different times. E) 4T1 cells irradiated with NIR laser after being treated with probe for different times. F) Survival rate of 4T1 cells treated with different drug concentrations and treatments determined by MTT assay, n = 6. G) TEM images of cells treated without probe or H) with probe (inset). I) CLSM of free DOX and DOX@Bi incubation with cell. *p < 0.05, **p < 0.01.\n1900017 (7 of 12) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nBi and DOX@Bi). After 12 h, the tumor sites were irradiated with an NIR laser for 10 min. The thermal images showed that the temperatures of Bi and DOX@Bi groups were significantly higher than those of PBS and DOX groups (Figure 6C,D), indicating that Bi has excellent photothermal performance.\nHistological section of tumor from one mouse (out of five mice) was implemented at 24 h after they received different therapies, while the remaining four mice were continuously observed. The H&E staining showed that most tumor cells from mouse receiving Bi or DOX@Bi with irradiation had no obvious integral cell morphology, which was significantly different from those from mouse receiving PBS with irradiation or Bi without irradiation. By contrast, morphology of the tumor cells from mouse receiving DOX with irradiation or DOX@Bi without irradiation was slightly changed, indicating that the thermal effect was able to kill tumor cell within a short period of time, while the chemotherapy was not. The TdT-mediated dUTP Nick-End Labeling (TUNEL) staining results further showed that tumor apoptosis was more obvious in mouse receiving Bi or DOX@Bi with irradiation, as indicated by a large number of apoptotic cell (brown). The tumor cells from mouse receiving DOX with irradiation or DOX@Bi without irradiation were partially brown, indicating they undergo apoptosis, whereas those from mice receiving PBS with irradiation or Bi without irradiation were not, indicating that they did not undergo apoptosis (Figure 7C). Five images representing\nAdv. Funct. Mater. 2019, 1900017\nFigure 6. A) CT image of tumor-bearing BALB/c mouse before and after injection. B) PAI of tumor site of tumor-bearing BALB/c mouse before and after injection. C) Thermal images of tumor-bearing mice after being injected with PBS, DOX, Bi and DOX@Bi for different times and D) the corresponding temperature changes; n = 5. E) Curves of tumor growth, F) body weight, and G) survival rate obtained after different treatments; n = 4. *p < 0.05, **p < 0.01.\n1900017 (8 of 12) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Funct. Mater. 2019, 1900017\nfive random areas of an entire tumor were taken, and the apoptosis positive rate was calculated. The results showed that the tumor cells from mouse receiving Bi or DOX@Bi with irradiation were significantly different from those from mouse in control group (Figure 7D). This demonstrates that Bi has an excellent photothermal performance.\nDuring the treatment, the average weight of mice in each group was found to decrease. Anesthesia was needed during the entire treatment process; it may result in mice's inability to eat, thereby causing their weight losses. However, the weight was gradually increased to the normal level after 6 d (Figure 6F). The change of tumor volume in mouse from each group was also examined. The results showed that the growth rate of tumor from mouse receiving PBS with irradiation group or Bi without irradiation was highest. The growth rate of tumor from mouse receiving DOX with irradiation or DOX@Bi without irradiation was significantly lower than those of other two groups (**p < 0.01). This indicates that although the chemotherapy can effectively slow down the tumor growth, it cannot kill tumor. Black scars were observed at the tumor site of mouse receiving Bi with irradiation or DOX@Bi with irradiation, which demonstrates that the two probes have superior PTT performances (Figure 7C). Compression test showed that the tumor was softened, compared with its original hard lump, and finally fell off. The average volumes of tumors were significantly different from those of the other four groups (**p < 0.01; Figure 6E).\nFigure 7. A) Curves for blood half-life and B) time-dependent biodistribution of Bi. C) Photographs of mice after different treatments for 24 h and their corresponding H&E/TUNEL-stained tumor. D) Histogram of apoptotic cell. E) A photograph of tumors from different groups of mice at the end of different treatments (14 d), *p < 0.05, **p < 0.01.\n1900017 (9 of 12) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Funct. Mater. 2019, 1900017\nHowever, with extended time after the treatment, cancer relapse was observed in mouse receiving Bi with irradiation; the recurrence rate was 75% after 10 d of treatment. On the other hand, the recurrence rate of cancer in mouse receiving DOX@Bi with irradiation was only 25%, and the tumor volume was much smaller than that from mouse receiving Bi with irradiation (Figure 7E). In accordance with the requirement for animal ethics, when the aggregate tumor is bigger than 1 cm in diameter, the tumor can impede vital activities, including eating, urination, defecation, or ambulation. Therefore, at this stage, the mice should be euthanized. Based on this information, the survival rate of mice receiving PBS with irradiation or Bi without irradiation was 0% at the end of the experiment (Figure 6G), while that of mice receiving Bi with irradiation or DOX@Bi with irradiation was 100%. Additionally, mice receiving DOX with irradiation and DOX@Bi without irradiation had survival rates of only 50% and 75%, respectively. These results show that combined chemo-photothermal therapy has significant therapeutic effect on tumor in mice, and the combined therapy is more efficacious than single-treatment therapy.\nTo examine the circulation time of the probe in mouse, as well as its distribution through various organs and tumor, the probe was injected into mouse through caudal vein. Blood sample was collected at various time points after injection, and its Bi content was measured. It was found the Bi-fitted curve of circulation half-life presented a classical two-compartment model,[24] in which the first and second phase blood circulation half-lives were 0.45 ± 0.07 h and 25.50 ± 0.74 h, respectively. It could be seen that the Bi in blood remained at a relatively stable level even at 36 h after injection (Figure 7A), which could help the probe transfer to the tumor site. A large amount of probe was enriched in the liver and spleen of mouse after 2 h. The probe was found to gradually enter into tumor, due to enhanced permeability and retention effect, reaching its maximum concentration in tumor at 10 h (Figure 7). It should be pointed out that the time points selected for this experiment were different from those selected for the imaging experiment so that we could prove that the imaging result is not a coincidence, rather it is an inevitable event for probe enrichment.\nThe colloidal stability of the nanoparticle had been studied in RPMI and RPMI+FBS culture medium as simulated blood. It could be seen that there was no obvious change in 15 d (Figure 8A–D), indicating that the probe had enough stability in blood.\nTo confirm the safety of the probe when used in vivo, biochemical values of blood from mouse were tested after injection. After the probe was injected through caudal vein into mouse, blood sample was collected at certain time points (Figure 8E–L). It is evident that there was no difference between red blood cell (RBC), white blood cell (WBC), platelet (PLT), and hemoglobin (HGB), the probe and control group, which demonstrated that the probe did not cause harm to mouse. Furthermore, influence of the probe on the functions of liver and kidney was studied using aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and alkaline phosphatase (ALP). The results showed that the biochemical values of blood samples were abnormal at 6 h after injection, but became normal after 3 d. These results indicate that the developed probe may be safe for use in vivo. In addition to\nblood analysis, the effect of the probe on major organs was also studied. Comparing the results of H&E-stained groups at 6 h, and 1, 3, and 7 d after injection with control group (Figure 8M), it was found that there was no change in the tissue structures of kidney, liver, lung, spleen, small intestine, and heart. Additionally, structure of the nucleus was clear without obvious cell necrosis. This indicates that the probe has no side effects and toxicity to these organs, further highlighting its safety."
    }, {
      "heading" : "3. Conclusion",
      "text" : "In this article, a low-price stomach medicine was used as the only raw material for the synthesis of nano-bismuth-spherecluster (Bi) that can be applied in dual-mode computed tomography-photoacoustic imaging. The synthesis is a one-step process conducted after an ultra-violet irradiation. The cluster was confirmed to be safe and have high photothermal conversion efficiency, uniform size, and excellent stability. Through simple centrifugal washing, the probe could be used directly in animal experiment after being adsorbed onto the antitumor drug doxorubicin. The results showed that Bi cluster could be effectively used in the dual-mode imaging as well as in combined chemo-photothermal therapy of tumor in vivo. The therapeutic effect of the Bi cluster in combination therapy was significantly higher than single therapy. This novel synthesized probe may be applied as a new method for early diagnosis and treatment of tumor."
    }, {
      "heading" : "4. Experimental Section",
      "text" : "Chemicals and Materials: Bismuth potassium citrate (BPC) granule was obtained from Livzon Pharmaceutical Group Inc. (Batch no. 1709134). 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT), calcein acetoxymethyl ester (calcein-AM), and propidium iodide (PI) were purchased from Aladdin. Doxorubicin hydrochloride (DOX) was purchased from Sangon Biotech. Nitric acid (guaranteed reagent) was purchased from Sinopharm Group Chemical Reagent Co., Ltd. BALB/c mice (male, 4-week old, specific pathogen free (SPF)) and Kunming mice (male, 4-week old, SPF) were purchased from Beijing Hufukang Bioscience Co. Inc. Mouse breast cancer cells (4T1) and mouse embryonic fibroblast cells (3T3) were purchased from Wuhan Hualianke Biotechnology Co., Ltd.\nInstrumentation: The instruments used in the experiments include a CPR-II-10T ultrapure water machine (Sichuan Ulupure Technology Co. Ltd., China), a WFX-200 atomic absorption spectrophotometer (Beijing Beifen-Ruili Analytical Instrument Co. Ltd., China), a Tissuelyser-24 multi-sample microstructure grinder (Shanghai Jingxin Industrial Development Co. Ltd., China), a Tecnai G20 U-Twin high-resolution transmission electron microscope (FEI, The Netherlands), a Nano-ZS90 nanometer size meter (Malvern, UK), an X'Pert PRO X-ray diffractometer (PANalytical B.V., The Netherlands), an Elx-808 microplate reader (Biotek, USA), a MDL-III-808-2.5W laser (Changchun New Industries Optoelectronics Tech. Co. Ltd., China), an EasIR-9 thermal imager (Wuhan Guide Infrared Co., Ltd., China), an IX71 fluorescence microscope (Olympus, Japan), a Pyris1 TGA thermogravimetric analyzer (PerkinElmer Instruments, China) and a AXIS-ULTRA DLD-600W X-ray photoelectron spectrometer (Shimadzu, Japan). CT and PAI were in-house systems called the in vivo animal CT imaging system[25] and the high-resolution photoacoustic imaging system,[26] respectively.\nSynthesis and characterization of nano-bismuth-sphere-cluster(Bi): BPC (0.4 mg) was dissolved in 25 mL of ultrapure water, and then irradiated with UV using a 300-W UV lamp for 3 min. After centrifugation at\n1900017 (10 of 12) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Funct. Mater. 2019, 1900017\n1900017 (11 of 12) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Funct. Mater. 2019, 1900017\npoured into ELISA plates, and then irradiated with an 808-nm laser (1.0 W cm−2) for 5 min. The temperature was recorded using a thermal camera. Probe at 0.25 mg mL−1 was also irradiated with an 808-nm laser with different power densities (0.5, 1.0, and 1.5 W cm−2) for 5 min. In each group, five parallel experiments were carried out. One milliliters of probe (0.5 mg mL−1) was transferred to a quartz cuvette, and then irradiated with an 808-nm laser with a power of 1.13 W for 10 min. After the laser power was turned off, the temperature was recorded, and the conversion efficiency was calculated according to the previously reported method.[20]\nEvaluation of probe in PAI and CT: Different concentrations of Bi suspensions (0.3, 0.6, 0.9, 1.2, and 1.5 mg mL−1) were transferred into PCR tubes and placed on a sample rack, and CT imaging using the in vivo animal CT imaging system was carried out. Matlab was used to reconstruct images and to read the CT value. Bi at the same concentrations as that used in CT imaging was also subjected to PAI, which was operated with a 744 nm, 120 nJ laser using the highresolution photoacoustic imaging system.\nSynthesis and characterization of DOX-loaded Bi cluster (DOX@Bi): DOX (40 µg) and Bi cluster (1 mg) were dissolved in 5 mL of PBS and then stirred for 12 h in darkness. After centrifugation at 8000 rpm for 10 min, the supernatant was discarded. This step was repeated three times to obtain the pellet containing DOX/Bi, which was then stored in darkness.\nBi and DOX were dispersed in PBS at different proportions; and the mixtures were stirred at room temperature for 12 h. After centrifugation (8000 rpm, 10 min), the supernatant was discarded; this step was repeated several times until the supernatant became colorless. The supernatant was combined and then subjected to measurement of absorption at 480 nm to determine mass of DOX. The encapsulation efficiency was calculated by the equation: [(massDOX-massDOX in supernatant)/massDOX] × 100%, while the loading efficiency was calculated using the equation: [(massDOX-massDOX in supernatant)/massprobe] × 100%.\nTo test pH-triggered drug release, two groups of DOX@Bi (0.6 mg) were dispersed in 3 mL of PBS with different pH (pH 5.4 and 7.4), placed in dialysis bags (molecular weight cut-off = 500 Da), and then dialyzed against solutions with the same pH values. Mass of DOX in dialysate was measured at various time intervals. The release rate of DOX was calculated by the equation: [total mass of released DOX/ amount of loaded DOX] × 100%.\nFor NIR-triggered drug release, two groups of DOX@Bi (0.6 mg) were dispersed in 1 mL of PBS (pH 7.4) in test tubes, which was then placed in a water bath at 37 °C for 12 h. At various time intervals, the sample was withdrawn from the tube, and then centrifuged at 8000 rpm for 10 min. The supernatant was collected for DOX detection, while the pellet was resuspended in PBS, irradiated with an 808-nm laser (1 W cm−2) for 5 min, and then subjected to centrifugation. The resultant supernatant was collected for DOX detection, and the pellet was resuspended in fresh PBS and was then stored at 37 °C. Six irradiations were carried out in 12 h. Other groups treated the same way but without laser irradiation were also prepared. Three parallel experiments were conducted.\nCytotoxicity of probe: 4T1 and 3T3 cells were evenly inoculated in a 96-well plate at a density of 104 cells per well, distributed over 40 wells. These wells were divided into eight groups and each group contained five parallel samples. The cells were treated with different concentrations of Bi suspensions (0, 15.6, 31.3, 62.5, 125, 250, 500, and 1000 µg mL−1) for 24 h; after that, 20 µL of MTT solution (5 mg mL−1) was added. After 4 h, the solution was replaced with 150 µL of DMSO, and the plate was shaken for 15 min. The cell survival rate was measured by absorbance at 490 nm.\nHemolysis assay: One milliliter of blood sample obtained from mice was diluted with 4 mL of PBS; after that, red blood cell was separated from the serum by centrifugation at 3000 rpm for 10 min. After being washed for at least five times, the red blood cell suspension was diluted with 5 mL of PBS. After that, 200 µL of the diluted cell suspension was mixed with 300 µL of PBS (negative control), ultrapure water (positive control) or at different concentrations of Bi (25, 50, 100,\n200, and 400 µg mL−1). After incubation at 37 °C for 1, 4, or 8 h, the mixture was centrifuged at 3000 rpm for 10 min. The supernatant was subsequently added into a 96-well plate, which was then subjected to measurement of absorbance using a microplate reader. The hemolysis percentage was calculated by the following equation: hemolysis ratio (%) = [(Asample − Acontrol(−))/(Acontrol(+) − Acontrol(−))] × 100%.\nStability of the Bi in RPMI and RPMI+FBS culture medium: Bi aqueous solution (1 mg mL−1) was added into RPMI and RPMI+FBS culture medium and exposed to 37 °C under air. They were sampled every 2 d to measure size, zeta potential, and particle dispersion index (PDI).\nPA/CT imaging and treatment of cell: After 4T1 cells were seeded in a cell culture flask for 24 h, they were treated with Bi (250 µg mL−1) for 0, 4, 8, or 12 h. After the cells were washed with PBS, they were immobilized with 2.5% glutaraldehyde; after that were carefully scraped off using a cell spatula and then collected for PAI and CT. Four groups of 4T1 cells were treated with Bi (250 µg mL−1) for 0, 4, 8, or 12 h. After the cells were washed with PBS, they were irradiated with an 808-nm laser (1.5 W cm−2) for 5 min. The cells were stained with calcein-AM and PI, and were then observed under a fluorescence microscope. Another part of the cell that was cultured with Bi for 12 h was washed and fixed with 2.5% glutaraldehyde for 24 h. The fixed cell was sliced into ultrathin sections and then observed by TEM.\n4T1 cells were seeded in a 96-well plate and allowed to adhere for 24 h in an incubator. The cells were exposed to free DOX, Bi and DOX@ Bi at various concentrations (0, 2, 4, 6, and 8 µg mL−1 for DOX; 0, 109.605, 219.21, 328.815, and 438.42 µg mL−1 for Bi) for 12 h. After that, the cells were washed three times with PBS to remove unbound probe. After irradiation by NIR laser (1.0 W cm−2) for 10 min (both treated and untreated cells), the cells were incubated at 37 °C for another 24 h. Subsequently, 20 µL of MTT solution (5 mg mL−1) was added into the cells and then incubated for 4 h. The solution was then replaced with 150 µL of DMSO, and the plate was shaken for 15 min. Finally, to determine cell survival rate, an absorbance at 490 nm of the cells was measured.\nConfocal laser scanning microscopy of free DOX and DOX@Bi: 4T1 cells were seeded into confocal capsule at 8 × 105 per well and treated with DOX (one group) or DOX@Bi (three groups) for 8 h. After removing the culture medium, PBS was used to wash the cells thrice to get rid of free probe. The cells with DOX and one group of cells with DOX@Bi were not irradiated by laser. Two groups of cells with DOX@Bi were irradiated by 808 nm laser (1.0 W cm−2) for 5 min, only one group was cultured for another 2 h after irradiation. All the cells were fixed with 2.5% glutaraldehyde and dyed using DAPI and LysoTracker Green DND, after which, they were observed using confocal laser scanning microscopy.\nPA/CT imaging of tumors in vivo: 4T1 cells were injected subcutaneously into BALB/c mice (male, SPF, 4 weeks). After the tumor grew to volumes of up to 60–100 mm3, imaging experiments were carried out. The mice were injected with DOX@Bi through caudal vein at a dose of 20 mg kg−1; after that they were subjected to PAI with a 744 nm laser (power = 140 nJ) and CT imaging. All animal experiments were approved by the Animal Experimental Ethics Committee of Huazhong University of Science and Technology, China.\nIn vivo PTT: Tumor-bearing mice with tumor volumes of 60–100 mm3 were divided into six groups (5 mice per group). Each group of mice was injected through caudal vein with 100 µL of different probes (dose of Bi: 20 mg kg−1; dose of DOX: 0.36 mg kg−1) with or without laser irradiation as follows: group (I), PBS + laser; group (II), DOX + laser; group (III) Bi; group (IV), Bi + Laser; group (V), DOX@Bi; and group (VI), DOX@Bi + Laser. The irradiation was carried out with an 808-nm laser at 1.5 W cm−2 for 10 min. The temperature of tumor site was recorded using a thermal camera. After 24 h, the tumor was removed from a mouse (one from each group) and then subjected to histopathological examination using Hematoxylin and Eeosin (H&E), and TdT-mediated dUTP Nick-End Labeling (TUNEL) staining. The changes of weight and tumor volume of the remaining four mice in each group were recorded every other day. The mice were regarded as being dead when the diameter of tumor reached 1 cm.\n1900017 (12 of 12) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Funct. Mater. 2019, 1900017\nIn vivo safety evaluation: Fifteen BALB/c mice (male, SPF, 4 weeks) were randomly divided into five groups. The mice were injected with DOX@Bi (Bi dose: 20 mg kg−1; DOX dose: 0.36 mg kg−1) through caudal vein. Blood samples (300 µL) of these mice were collected at 6 h, and 1, 3, and 7 d. 200 µL of the samples were used for liver enzyme analysis (aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN) and alkaline phosphatase (ALP)); and another 100 µL of the samples was used in blood analysis (red blood cell (RBC), white blood cell (WBC), platelet (PLT) and hemoglobin (HGB)). Major organs including heart, liver, spleen, lung, kidney, and small intestine were also collected. After they were fixed with 4% paraformaldehyde, dehydrated, and sliced, they were stained with H&E (in histopathological examination) and then observed under a microscope. Five mice without any treatment were used as a blank control. Their blood and main organs were also collected for the same analyses.\nHalf-life and distribution of probes in vivo: The probe (Bi; 200 µL; dose: 20 mg kg−1) was injected into Kunming mice through caudal vein. Blood samples (40 µL) were collected from the caudal vein at different time points (10 and 30 min, and 1, 2, 4, 8, 12, 24, and 48 h; n = 3). After the blood was dissolved in nitric acid, its bismuth content was determined using an atomic absorption spectrophotometer.\nAfter the tumor volume reached 60–100 mm3, BALB/c mice were injected through caudal vein with 100 µL of probe (Bi; dose: 20 mg kg−1). After that, they were killed at different time points (2, 5, and 10 h, and 1, 3 and 7 d; n = 3). Their main organs and tumor were weighed and ground, and were thereafter dissolved in nitric acid for the determination of bismuth content."
    }, {
      "heading" : "Acknowledgements",
      "text" : "X.Y. and X.-Q.Y. contributed equally to this work. This work was supported by the National Key Research and Development Program of China (2017YFA0700501), the National Natural Science Foundation of China (Grant No. 81771878), and the Fundamental Research Funds for the Central Universities (Hust: 2016YXMS253, 2017KFXKJC002, 2018KFYXKJC048). The authors also thank the Analytical and Testing Center (HUST), the Research Core Facilities for Life Science (HUST), and the Center for Nanoscale Characterization & Devices (CNCD) at WNLO of HUST for the help of measurement."
    }, {
      "heading" : "Conflict of Interest",
      "text" : "The authors declare no conflict of interest."
    }, {
      "heading" : "Keywords",
      "text" : "chemo-photothermal therapy, drug release, dual-mode imaging, gastric drug, one-step synthesis\nReceived: January 1, 2019 Revised: February 15, 2019\nPublished online:\n[1] Y. Cheng, R. A. Morshed, B. Auffinger, A. L. Tobias, M. S. Lesniak, Adv. Drug Delivery Rev. 2014, 66, 42. [2] M. Liong, J. Lu, M. Kovochich, T. Xia, S. G. Ruehm, A. E. Nel, F. Tamanoi, J. I. Zink, ACS Nano 2008, 2, 889. [3] J. Kim, H. Kim, N. Lee, T. Kim, H. Kim, T. Yu, I. Song, W. Moon, T. Hyeon, Angew. Chem., Int. Ed. 2008, 47, 8438. [4] K. Li, S. Wen, A. C. Larson, M. Shen, Z. Zhang, Q. Chen, X. Shi, G. Zhang, Int. J. Nanomed. 2013, 8, 2589. [5] S. Zeng, M. Tsang, C. Chan, K. Wong, J. Hao, Biomaterials 2012, 33, 9232. [6] X. S. Zhang, Y. Xuan, X. Q. Yang, K. Cheng, R. Y. Zhang, C. Li, F. Tan, Y. C. Cao, X. L. Song, J. An, X. L. Hou, Y. D. Zhao, J. Nanobiotechnol. 2018, 16, 42. [7] H. Xing, W. Bu, S. Zhang, X. Zheng, M. Li, F. Chen, Q. He, L. Zhou, W. Peng, Y. Hua, J. Shi, Biomaterials 2012, 33, 1079. [8] A. Rosengren, L. Wilhelmsen, Eur. J. Epidemiol. 2004, 19, 533. [9] J. An, X. Q. Yang, K. Cheng, X. L. Song, L. Zhang, C. Li, X. S. Zhang,\nY. Xuan, Y. Y. Song, B. Y. Fang, X. L. Hou, Y. D. Zhao, B. Liu, ACS Appl. Mater. Interfaces 2017, 9, 41748. [10] Z. Y. Ma, Y. P. Liu, L. Y. Bai, J. An, L. Zhang, Y. Xuan, X. S. Zhang, Y. D. Zhao, Dalton Trans. 2015, 44, 16304. [11] V. U. Fiedler, H. J. Schwarzmaier, F. Eickmeyer, F. Muller, C. Schoepp, P. R. Verreet, J. Magn. Reson. Imaging 2001, 13, 729. [12] U. Lindner, R. A. Weersink, M. A. Haider, M. R. Gertner, S. R. H. Davidson, M. Atri, B. C. Wilson, A. Fenster, J. Trachtenberg, J. Urol. 2009, 182, 1371. [13] J. You, G. Zhang, C. Li, ACS Nano 2010, 4, 1033. [14] Z. Zhang, J. Wang, X. Nie, T. Wen, Y. Ji, X. Wu, Y. Zhao, C. Chen,\nJ. Am. Chem. Soc. 2014, 136, 7317. [15] H. X. Xia, X. Q. Yang, J. T. Song, J. Chen, M. Z. Zhang, D. M. Yan,\nL. Zhang, M. Y. Qin, L. Y. Bai, Y. D. Zhao, Z. Y. Ma, J. Mater. Chem. B 2014, 2, 1945. [16] M. P. Melancon, W. Lu, Z. Yang, R. Zhang, Z. Cheng, A. M. Elliot, J. Stafford, T. Olson, J. Zhang, C. Li, Mol. Cancer Ther. 2008, 7, 1730. [17] S. C. Warren, A. C. Jackson, Z. D. Cater-Cyker, F. J. DiSalvo, U. Wiesner, J. Am. Chem. Soc. 2007, 129, 10072. [18] S. Santana-Viera, S. Montesdeoca-Esponda, Z. Sosa-Ferrera, J. J. Santana-Rodríguez, TrAC Trends in Anal. Chem. 2016, 80, 373. [19] H. S. Liang, L. He, B. Zhou, B. Li, J. Li, Colloids Surf., B 2017, 156, 19. [20] Y. Xuan, R. Y. Zhang, X. S. Zhang, J. An, K. Cheng, C. Li, X. L. Hou,\nY. D. Zhao, Nanotechnology 2018, 29, 355101. [21] Y. Yang, H. Wu, B. Shi, L. Guo, Y. Zhang, X. An, H. Zhang, S. Yang,\nPart. Part. Syst. Charact. 2015, 32, 668. [22] Q. Tian, F. Jiang, R. Zou, Q. Liu, Z. Chen, M. Zhu, S. Yang, J. Wang,\nJ. Wang, J. Hu, ACS Nano 2011, 5, 9761. [23] P. Lei, R. An, P. Zhang, S. Yao, S. Song, L. Dong, X. Xu, K. Du,\nJ. Feng, H. Zhang, Adv. Funct. Mater. 2017, 27, 1702018. [24] P. Lei, R. An, X. Zheng, P. Zhang, K. Du, M. Zhang, L. Dong,\nX. Gao, J. Feng, H. Zhang, Nanoscale 2018, 10, 16765. [25] D. Yan, Z. Zhang, Q. Luo, X. Yang, PLoS One 2017, 12, e0169424. [26] X. Yang, B. Jiang, X. Song, J. Wei, Q. Luo, Opt. Express 2017, 25,\n284507. [27] O. Rabin, J. M. Perez, J. Grimm, G. Wojtkiewicz, R. Weissleder,\nNat. Mater. 2006, 5, 118."
    } ],
    "references" : [ {
      "title" : "Chem",
      "author" : [ "H.X. Xia", "X.Q. Yang", "J.T. Song", "J. Chen", "M.Z. Zhang", "D.M. Yan", "L. Zhang", "M.Y. Qin", "L.Y. Bai", "Y.D. Zhao", "Z.Y. Ma", "J. Mater" ],
      "venue" : "B 2014, 2",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 1945
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Some nanomaterials for imaging, such as gold nanorod/ shell/star[9,15,16] and Ag2S quantum dot,[6] have also been found to possess photothermal property.",
      "startOffset" : 64,
      "endOffset" : 73
    } ],
    "year" : 2019,
    "abstractText" : "Multifunctional nanoprobes that can be applied for real-time monitoring or precision treatment of tumors have received wide interest among researchers. However, most of these nanoprobes are obtained through chemical synthesis, and thereby may contain toxic residues or harmful reagents. In this article, a nano-bismuth-sphere-cluster (Bi) is synthesized via a one-step method (after an irradiation with ultra-violet) and is then applied in dual-mode computed tomography/photoacoustic imaging. Bismuth potassium citrate granules, which is a common gastric drug that is highly safe and has a low price (<1 China Yuan/g), is used as the only raw material. The results show that the Bi cluster has good stability with sizes of about 25–55 nm, and a photothermal conversion efficiency as high as 39.67%. After being adsorbed onto doxorubicin, the Bi cluster can be used directly in animal experiments. Due to the effect of enhanced permeability and retention, the probe can easily enter tumor cells. Drug release can be controlled by a near-infrared laser and the acidic environment of tumor cells, which indicates that the combined chemo-photothermal therapy is achieved. This work presents a new dual-mode bio-imaging and combined chemo-photothermal therapeutic nanoprobe that can be applied in theragnostics for tumors.",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}